REG - Nuformix PLC - Director/PDMR Shareholding

NuformixAnnouncement

10/01/2022 16:25

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220110:nRSJ9789Xa&default-theme=true

RNS Number : 9789X  Nuformix PLC  10 January 2022

10 January 2022

Nuformix plc

 

("Nuformix" or the "the Company")

 

Director/PDMR Shareholding

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that
today the Company received notice that Dr Alastair Riddell purchased 400,000
ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 1.175
pence per share on 10 January 2022.

 

- Ends -

 

 Nuformix plc                                            via Walbrook
 Dr Alastair Riddell, Executive Chairman

 Allenby Capital Limited                                 +44 (0) 20 3328 5656
 Nick Athanas / George Payne (Corporate Finance)
 Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)

 Walbrook PR        nuformix@walbrookpr.com (mailto:nuformix@walbrookpr.com)  or +44 (0)20 7933
                    8780
 Anna Dunphy / Phillip Marriage        Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082

 Enquiries:

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Dr Alastair Riddell

 2    Reason for the notification

 a)   Position/status                                              PDMR - Executive Chairman

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Nuformix plc

 b)   LEI                                                          2138003XG3H3I2J3BJ24

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of nominal value 0.1 pence each

      Identification code

                                                                   GB00BYW79Y38
 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

Price(s)  Volume(s)

                                                                   1.175p    400,000

 d)   Aggregated information

      - Aggregated volume                                          400,000

      - Price                                                      1.175p

      - Total                                                      £4,700.00
 e)   Date of the transaction                                      10 January 2022

 f)   Place of the transaction                                     London Stock Exchange, Main Market

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

- Total

 

 

400,000

 

1.175p

 

£4,700.00

e)

 

Date of the transaction

 

10 January 2022

f)

 

Place of the transaction

 

London Stock Exchange, Main Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGPUUPGUPPGQU